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Abstract
AIMS: To demonstrate the synergistic antiproliferative and proapoptotic activity of irinotecan and axitinib in vitro
and the improvement of the in vivo effects on angiogenesis and pancreatic cancer.METHODS: Proliferation and apop-
totic assays were performed on human dermal microvascular endothelial cells and pancreas cancer (MIAPaCa-2,
Capan-1) cell lines exposed to SN-38, the active metabolite of irinotecan, axitinib, or their simultaneous combination
for 72 hours. ERK1/2 and Akt phosphorylation, the vascular endothelial growth factor (VEGF), VEGF receptor-2, and
thrombospondin-1 (TSP-1) concentration were measured by ELISAs. ATP7A and ABCG2 gene expression was per-
formed with real-time polymerase chain reaction and SN-38 intracellular concentrations were measured by high-
performance liquid chromatography. Capan-1 xenografts in nude mice were treated with irinotecan and axitinib alone
or in simultaneous combination. RESULTS: A strong synergistic effect on antiproliferative and proapoptotic activity
was found with the axitinib/SN-38 combination on endothelial and cancer cells. ERK1/2 and Akt phosphorylation were
significantly inhibited by lower concentrations of the combined drugs in all the cell lines. Axitinib and SN-38 combined
treatment greatly inhibited the expression of the ATP7A and ABCG2 genes in endothelial and cancer cells, increas-
ing the SN-38 intracellular concentration. Moreover, TSP-1 secretion was increased in cells treated with both drugs,
whereas VEGFR-2 levels significantly decreased. In vivo administration of the simultaneous combination determined
an almost complete regression of tumors and tumor neovascularization. CONCLUSIONS: In vitro results show the
highly synergistic properties of simultaneous combination of irinotecan and axitinib on endothelial and pancreas
cancer cells, suggesting a possible translation of this schedule into the clinics.
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Introduction
Axitinib (AG-013736), a novel multitarget tyrosine kinase inhibitor,
has been recently introduced in clinical trials, often in combination
with chemotherapeutic drugs [1] as a potent, oral antiangiogenic drug,
mainly targeting the vascular endothelial growth factor receptor-2
(VEGFR-2) tyrosine kinase domain [2–4]. A number of preclinical
studies have been published on this compound, showing an in vivo
antitumor activity in breast [5], prostate [6–8], exocrine and endocrine
pancreas [4,9], colon, renal cell, and ovarian cancer [4]. The in vivo
antitumor effects were mainly due to the antiangiogenic property of
the molecule as demonstrated by immunohistochemistry (IHC) [5,9]
and dynamic contrast-enhanced magnetic resonance imaging [5]. Some
combination therapies has been tested in vivo to increase the antitumor
activity of the compound. Metronomic and standard doses of cyclo-
phosphamide [6,10], gemcitabine, docetaxel, and carboplatin [4] have
been successfully used in vivo in human pancreas, breast, and ovarian
cancer xenografts.
Pancreatic cancer is a leading cause of tumor deaths among oncologic
diseases. The 5-year survival in early diagnosed and surgically treated
patients ranges from 12% to 20% [11]. Metastatic pancreatic cancer
remains resistant to current chemotherapy and radiotherapy. Although
gemcitabine is the main used drug for systemic treatment of pancreatic
cancer patients, it does not significantly prolong the survival of the
patients. Alternative therapeutic options are urgently needed to im-
prove the tumor response and survival. For these reasons, numerous
combinations have been assessed in preclinical studies, usually using
gemcitabine combined with various drugs such as fluvastatin [12]
and antiangiogenic agents [13–15]. Irinotecan (CPT-11) is a standard
therapeutic choice for colorectal cancer, but few phase 1 to 2 clinical
studies, combining gemcitabine with irinotecan [16,17], to treat pan-
creatic cancer have been undertaken; moreover, a few preclinical studies
assessing single drug administration [18,19] or its combination with
GEM231, a second-generation antisense oligonucleotide [20] or
TRA-8, an agonistic antibody to death receptor 5 [21], have been re-
cently assessed in pancreas cancer.
Cellular drug resistance is a major obstacle in pancreas cancer ther-
apy. Cancer cells can be intrinsically resistant or acquire resistance to
both cytotoxic and novel molecularly targeted drugs. This form of
multidrug resistance can be conveyed by several mechanisms includ-
ing the active ATP-dependent transport of drugs out of the cell by
efflux pumps belonging to the ATP-binding cassette (ABC) family
of transporters [22]. ABCG2 overexpression has been associated with
a marked decrease in the intracellular accumulation of SN-38, the
active metabolite of irinotecan, and with the highest resistance level
of colorectal and endometrial cancer cells, confirming that ABCG2
is directly involved in acquired resistance to SN-38 [23,24]. More-
over, the copper-transporting P-type ATPase ATP7A has been recently
implicated in multidrug resistance to chemotherapy by enhancing
efflux of drugs such as cisplatin, paclitaxel, doxorubicin, and SN-38
[25,26]. These findings strongly suggest that both ABCG2 and
ATP7A expression could modulate the efflux rates of SN-38 from
cancer cells.
Thus, our approach to combination therapy studies in pancreas
cancer involves both irinotecan and axitinib to answer to the open
issue about tumor responsiveness. The purposes of our study were 1)
to demonstrate the synergistic interaction in vitro between SN-38
and axitinib in endothelial/pancreas cancer cells and an improvement
of anticancer activity in vivo by the simultaneous combination of
irinotecan and axitinib and 2) to elucidate the molecular mechanisms
of the antiproliferative and proapoptotic activities that may be mediated
by this particular combination treatment.
Materials and Methods
In Vitro Studies
Materials, drugs, and cells lines. Recombinant human vascular
endothelial growth factor (rhVEGF) and recombinant human epider-
mal growth factor (rhEGF) were from PeproTechEC Ltd (London,
UK). Cell culture media MCDB131, RPMI, and Dulbecco modi-
fied Eagle medium; fetal bovine serum (FBS); horse serum (HS);
L-glutamine; penicillin; streptomycin; and antibiotics were from Gibco
(Gaithersburg, MD). Type A gelatin from porcine skin, supplements,
and all other chemicals not listed in this section were obtained from
Sigma Chemical Co (St Louis, MO). Plastics for cell culture were
supplied by Costar (Cambridge, MA).
Axitinib and irinotecan and its active metabolite SN-38 were
kindly provided by Pfizer (Groton, MD). For the in vitro experi-
ments, the drugs were dissolved in DMSO and diluted as needed;
for the in vivo studies, irinotecan was diluted in saline and adminis-
tered intraperitoneally (i.p.), whereas axitinib was formulated in
0.5% carboxymethylcellulose/H2O·HCl (g/v, pH 2-3) and dosed
as a suspension at 5 ml/kg orally twice daily [4].
The human dermal microvascular endothelial cells (HMVEC-d;
Clonetics, San Diego, CA) were maintained in MCDB131 culture
medium supplemented with antibiotics, 10% heat-inactivated FBS,
L-glutamine (2 mM), heparin (10 IU/ml), rhEGF (10 ng/ml), and
basic fibroblast growth factor (5 ng/ml). The human pancreatic cancer
cell line MIAPaCa-2 was obtained from the American Type Culture
Collection (ATCC, Manassas, VA), maintained in Dulbecco modified
Eagle medium, and supplemented with 10% FBS, 2.5% HS, antibio-
tics and L-glutamine. The human pancreatic cancer cell line Capan-1
was obtained from the ATCC, maintained in RPMI medium, and
supplemented with 15% FBS, L-glutamine, and antibiotics.
Cell proliferation assay. HMVEC-d (6 × 104 cells/well), Capan-1
(2 × 104 cells/well), and MIAPaCa-2 (2 × 104 cells/well) cells were
plated in 24-well plates (1% gelatin-coated for HMVEC-d) and allowed
to attach overnight. Endothelial cells were treated with axitinib (0.01-
1000 nM) and SN-38 (0.001-1000 nM) or with their vehicles con-
tinuously for 72 hours in 1 ml of medium, adding fresh medium with
drugs every 24 hours. In separate experiments, tumor cell lines were
treated with axitinib (0.001-100 μM) and SN-38 (0.001-100 μM) or
with their vehicles for 72 hours. At the end of the treatment, the cells
were harvested with trypsin/EDTA, and the viable cells were counted
with a hemocytometer; the growth of treated cells was expressed as a
percentage of control cultures (vehicle alone). The concentration of
drugs that decreased cell count by 50% (IC50) compared with controls
was calculated by nonlinear fitting of experimental data. All experi-
ments were repeated, independently, three times with at least nine
samples for each concentration.
In vitro assessment of synergism between axitinib and SN-38 on
endothelial and tumor cells. The combination of SN-38 and
axitinib was explored with the treatment schedule at a simultaneous
exposure with a fixed molar concentration ratio of 1:1 on HMVEC-d
and MIAPaCa-2 cells or 1:10 on Capan-1 cells for 72 hours. To
evaluate the level of interaction (synergistic, additive, or antagonistic)
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between SN-38 and axitinib, the method proposed by Chou [27] was
followed. Briefly, synergism or antagonism for axitinib plus SN-38
was calculated on the basis of the multiple drug-effect equation and
quantified by the combination index (CI), where CI < 1, CI = 1,
and CI > 1 indicate synergism, additive effect, and antagonism, respec-
tively. On the basis of the classic isobologram for mutually exclusive
effects, the CI value was calculated as follows:
CI = ½ðDÞ1 = ðDxÞ1 + ½ðDÞ2 = ðDxÞ2
As an example, at the 50% inhibition level, (Dx)1 and (Dx)2 are the
concentrations of axitinib and SN-38, respectively, that induce a
50% inhibition of cell growth; (D)1 and (D)2 are the concentrations
of axitinib and SN-38 in combination that also inhibits cell growth
by 50% (isoeffective as compared with the single drugs alone). The
dose reduction index (DRI) defined the degree of dose reduction that
is possible in a combination for a given degree of effect as compared
with the concentration of each drug alone:
ðDRIÞ1 = ðDxÞ1 = ðDÞ1 and ðDRIÞ2 = ðDxÞ2 = ðDÞ2
The CI and DRI indexes were calculated with the CalcuSyn v.2.0
software (Biosoft, Cambridge, UK).
Apoptosis measurements. To quantify the apoptotic process, endo-
thelial and cancer cells were treated for 72 hours with axitinib (0.01-
1000 nM), SN-38 (0.01-1000 nM), and the simultaneous axitinib/
SN-38 combination and vehicle alone. At the end of the experiment,
cells were collected and the Cell Death Detection ELISA Plus kit
(F. Hoffmann-La Roche Ltd, Basel, Switzerland) was used. All the
absorbance values were plotted as a percentage of apoptosis relative
to control cells (vehicle only), labeled as 100%. All experiments were
repeated three times with at least three replicates per sample.
ERK1/2 (pTpY185/187) and Akt (pThr308) ELISA assay. To
detect the phosphorylation of ERK1/2 and Akt in endothelial and can-
cer cells after a 72-hour drug treatment, cells were exposed to axitinib,
SN-38, and their simultaneous combination (1:1 or 1:10 fixed molar
concentration) at concentrations corresponding to the experimental
IC50 of cell proliferation or with vehicle alone for 72 hours. To mea-
sure pERK1/2 and pAkt, at the end of the experiment, the cells were
harvested and immediately frozen with liquid nitrogen. Cells were
lysed as per manufacturer’s instructions. Each sample was then assayed
for human ERK1/2 and Akt phosphorylation by the PhosphoDetect
ERK1/2 (pThr185/pTyr187) ELISA Kit and the PhosphoDetect Akt
(pThr308) ELISA Kit (Calbiochem, Darmstadt, Germany) and normal-
ized by total protein ERK1/2 and Akt concentration, respectively. The
optical density was determined using the microplate reader Multiskan
Spectrum (Thermo Labsystems, Milan, Italy) set to 450 nm. The re-
sults were expressed as percentage of pERK1/2 and pAKTof controls.
All experiments were repeated, independently, six times with at least
nine samples for each concentration.
Real-time polymerase chain reaction analysis of ATP7A and
ABCG2 gene expression on tumor and endothelial cells. To eval-
uate the expression of the human ATP7A and ABCG2 genes, 6 ×
104 HMVEC-d, 2 × 104 MIAPaCa-2 and Capan-1 cells were grown
in their respective media and treated with axitinib, SN-38, and their
simultaneous combination at a concentration corresponding to the
experimental IC50 of cell proliferation and at higher and lower doses
or with vehicle alone for 72 hours. Briefly, RNA (1 μg) was reverse
transcribed as previously described [28], and the resulting comple-
mentary DNA was diluted (2:3) and then amplified by quantitative
reverse transcription–polymerase chain reaction with a sequence de-
tection system (7900HT; Applied Biosystems, Carlsbad, CA). ATP7A-
andABCG2-validated primers were purchased fromApplied Biosystems
(Assay ID Hs00921967_m1 and Hs01053796_m1, respectively). The
polymerase chain reaction thermal cycling conditions and optimization
of primer concentrations were followed as per manufacturer’s instruc-
tions. Amplifications were normalized to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), and the quantitation of gene expression
was performed using the ΔΔC t calculation, where C t is the threshold
cycle; the amount of target, normalized to the endogenous control and
relative to the calibrator (vehicle-treated control cells), is given as 2−ΔΔCt.
All experiments were repeated, independently, three times with at least
nine samples for each concentration.
High-performance liquid chromatography analysis of SN-38 concen-
trations in endothelial cells. The quantitative analysis of irinotecan’s
main metabolite SN-38 in cells was performed as previously described
[29] with minor modifications. Endothelial cells were treated with
vehicle alone, SN-38 (1 μM), axitinib (1 μM), or a combination of
the two (SN-38 1 μM + axitinib 1 μM) for 72 hours. At the end of
the experiment, the cells were collected, counted to obtain the same
number of cells in each sample (105 cells), and centrifuged. The cells
were frozen and thawed three times consecutively. Briefly, concen-
trations of SN-38 were evaluated after extracting with methanol con-
taining 0.1% HCl 10 N. The samples were then centrifuged, and
the clear supernatant was evaporated to dryness under nitrogen flow
in a thermostated bath at 45°C. The resulting pellet was reconstituted
in methanol acidified with 0.1% HCl 10 N and eluted through a
μBondapack C18 stationary phase column (300 × 3.9 mm, 10 μm;
Waters, Milford, MA) by KH2PO4 0.1 M/acetonitrile (60:40, vol/
vol; pH 6.0) containing 3 mM sodium heptanesulfonate. The chro-
matographic system LC Module I Plus (Waters) was equipped with a
Model 474 scanning fluorescence detector with excitation and emis-
sion wavelengths set at 375 and 525 nm, respectively. Data analysis
was performed using Millennium 2.1 software (Waters). Standard cali-
bration curves were generated by adding SN-38 to 1 ml of PBS, re-
sulting in final concentrations that ranged from 2500 to 0.16 ng/ml.
The range of linearity of the high-performance liquid chromatography
method was from 2500 to 0.16 ng/ml.
VEGF, thrombospondin-1, and VEGFR-2 detection in condi-
tioned media and cell lysate by ELISA. HMVEC-d, Capan-1,
and MIAPaCa-2 cells were grown in their respective media and treated
with SN-38 and axitinib at a concentration corresponding to the experi-
mental IC50 of cell proliferation and at higher and lower concentrations
or using simultaneous combination treatment. To measure secreted
VEGF and thrombospondin-1 (TSP-1), at the end of the experiment,
the medium of each well was discarded and replaced with serum-
free medium for 4 hours. Each sample was then assayed for human
VEGF and TSP-1 concentrations by the VEGF and TSP-1 ELISA
Kit Quantikine (R&D System, Minneapolis, MN), respectively, and
normalized by total protein concentration. The sVEGFR-2 ELISA
KitQuantikine (R&DSystems) was used tomeasure VEGFR-2 protein
concentrations in the endothelial cell lysate; the results were normalized
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per number of cells. The optical density was determined using the
microplate reader Multiskan Spectrum set to 450 nm (with a wave-
length correction set to 540 nm). All experiments were repeated, inde-
pendently, three times with at least nine samples for each concentration.
In Vivo Studies
Animals and treatments. The CD nu/nu male mice, weighing
20 g, were supplied by Charles River (Milan, Italy) and were allowed
unrestricted access to sterile food and tap water. Housing and all pro-
cedures involving animals were performed according to the protocol
approved (approval no. 2741) by theComitato di Ateneo per la sperimen-
tazione animale (Academic Committee for the animal experimentation)
of the University of Pisa, in accordance with the European Community
Council Directive 86-609, recognized by the Italian government, on
animal welfare. Each experiment used the minimum number of mice
needed to obtain statistically meaningful results.
On day 0, 2 × 106 ± 5% viable Capan-1 cells/mouse were inocu-
lated subcutaneously. Animal weights were monitored, and on appear-
ance of a subcutaneous mass, tumor dimensions were measured every
2 days using calipers. Tumor volume (mm3) was defined as follows:
[(w1 × w1 × w2) × (π/6)], where w1 and w2 were the largest and the
smallest tumor diameter (mm), respectively. The mice were random-
ized into groups of six animals. Treatment was delivered once the
tumor reached ∼100 mm3, from day 8 to 10 after cell inoculation.
Axitinib, irinotecan, or their simultaneous combination was adminis-
tered as follows: 1) axitinib 25 mg/kg per os (p.o.) twice a day for
31 days, 2) irinotecan 100 mg/kg weekly for 4 weeks, 3) simultaneous
combination of axitinib and irinotecan at each of the above schedules.
Mice from the control group were injected i.p. with saline and p.o.
with vehicle alone. The experimental period ended 7 days after the last
administration of axitinib. Mice were killed by an anesthetic overdose,
and tumors were excised, measured, and sampled for IHC. Drug effi-
cacy was based on percentage of the average treated tumor volume di-
vided by the average vehicle control tumor volume (% T /C) [28].
Immunohistochemistry. Briefly, tumor tissue samples from all the
different treatment groups were fixed in 10% neutral-buffered for-
malin for 12 to 24 hours and embedded in paraffin for histology and
IHC. Sections of the tumor (5 μm thick) were stained with hematoxy-
lin and eosin. Immunostainings were performed by a Benchmark im-
munostainer (Ventana, Tucson, AZ) using the avidin-biotin-peroxidase
complex (ABC) method and counterstained with hematoxylin. Nega-
tive controls were carried out by omitting the primary antibodies. IHC
evaluated independently by two pathologists (G.A. and G.F.) blinded
to the treatment code.
Microvascular count was determined using anti-FVIII polyclonal
antibody (Ventana Medical System). A single microvessel was defined
as any immunostained endothelial cell separated from adjacent micro-
vessel, tumor cells, and other connective tissue elements. Samples
were examined by each pathologist, who identified the area with most
intense vascularization (hot spot) under low microscopic power
(×100). A region of 0.74 mm2/field was then scanned at ×250 micro-
scope magnification. Five fields were analyzed, and for each of them,
the number of stained blood vessels was counted. For individual tu-
mors, microvascular count was scored by averaging the five field
counts. Large vessels with thick, muscular walls were excluded from
the counts. The presence of a lumen was not required for scoring as
a microvessel.
IHC detection of apoptosis-related protein was carried out using
a rabbit polyclonal antibody to active caspase-3 (diluted 1:2000;
Abcam, Cambridge, UK) that specifically recognizes the large frag-
ment (17 kDa) of the active protein but not full-length caspase-3.
The antibody selectively stained the cytoplasm of apoptotic cells.
The apoptotic index (AI) was obtained by examination of the sec-
tions stained using IHC and all the identifiable cells exhibiting stain-
ing were counted. Apoptotic cells, which were present in areas where
intense necrosis had occurred, were excluded from analysis. AI was
calculated as a percentage of the apoptotic cells out of the total num-
ber of the examined cells [30,31].
Statistical analysis. The analysis by analysis of variance, followed by
the Student-Newman-Keuls test, was used to assess the statistical dif-
ferences of data in vitro and in vivo. P < .05 was considered significant.
Statistical analyses were performed using the GraphPad Prism software
package version 5.0 (GraphPad Software, Inc, San Diego, CA).
Results
Axitinib and SN-38 Inhibit Endothelial and Cancer Cell
Proliferation In Vitro
In vitro axitinib and SN-38 inhibited the cell proliferation of
HMVEC-d and of the pancreatic cancer cell line Capan-1 and
MIAPaCa-2 in a concentration-dependent manner (Figure 1); the
72-hour axitinib exposure inhibited the proliferation of HMVEC-d
with an IC50 of 30.5 ± 12.9 nM (Figure 1A), being significantly dif-
ferent from those observed in MIAPaCa-2 and Capan-1 (0.80 ± 0.35
and 0.84 ± 0.34 μM, respectively; Figure 1, B and C ). In contrast, a
greater antiproliferative effect of SN-38 on Capan-1 and MIAPaCa-2
was found as demonstrated by the IC50 values (0.040 ± 0.032 and
0.29 ± 0.023 μM, respectively; Figure 1, B and C ). The cytotoxic
activity on proliferating HMVEC-d was similar to the one observed
with axitinib (IC50, 13.3 ± 4.7 nM; Figure 1A).
Synergistic Effect of Axitinib and SN-38 on HMVEC-d,
Capan-1, and MIAPaCa-2 Cell Proliferation
Simultaneous and continuous exposure of HMVEC-d, MIAPaCa-2,
and Capan-1 cells to different concentrations of SN-38 and axitinib
for 72 hours showed a strong synergism (CI < 1 and DRI > 1; Table 1).
Synergism corresponding to CI < 1 always yielded a favorable DRI >
1 for both drugs (Table 1). The CI and DRI values at IC25, IC50,
and IC75 are reported in Table 1. Figure 1D shows a representative
isobologram of HMVEC-d cells exposed to axitinib and SN-38 for
72 hours with the simultaneous schedule of treatment. Furthermore,
the simultaneous treatments of axitinib and SN-38 for 72 hours were
synergistically active on pancreatic Capan-1 and MIAPaCa-2 cell pro-
liferation, as shown by the representative isobolograms in Figure 1,
E and F, respectively. The position of the data points on the left of
the line connecting the IC50 and IC90 values of axitinib and SN-38
indicates synergism for the schedule (Figure 1, D-F ).
Induction of Apoptosis by Axitinib, SN-38, and
Their Combination
The extent of DNA fragmentation was dependent on the concen-
tration of both drugs. In particular, the presence of chromatin frag-
ments was clearly detectable after 72 hours in a dose-dependent
manner for axitinib and SN-38, alone and simultaneously combined
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(Figure 2). As shown in the upper part of Figure 2A, after 72 hours
of treatment with axitinib and SN-38, a significant percentage of
apoptotic endothelial cells in the treated samples were found when
compared to controls. These percentages were similar to those ob-
tained when cells were treated at much lower concentrations in the
simultaneous axitinib/SN-38 combination (Figure 2A, lower part).
Furthermore, the same proapoptotic effects of axitinib and SN-38,
alone and in combination, were observed also in both cancer cell
lines Capan-1 and MIAPaCa-2 (Figure 2, B and C , respectively).
Inhibition of ERK1/2 and Akt Phosphorylation in Endothelial
and Cancer Cells by the Drug Combination
After exposure to SN-38, axitinib, and their simultaneous combi-
nation at the concentration corresponding to experimental IC50 of
cell proliferation reduced the amount of the active, phosphorylated
form of ERK1/2 and Akt in HMVEC-d cells (Figure 3A). The ratio
of phosphorylated/nonphosphorylated ERK1/2 and Akt proteins of
treated cells seemed significantly decreased also in Capan-1 and
MIAPaCa-2 cells, respectively (Figure 3, B and C ). Interestingly,
the combination of the two drugs synergistically enhanced the inhi-
bition of phosphorylation of both ERK1/2 and Akt in all the tested
cell lines; indeed, much lower concentrations of the combined drugs
obtained similar inhibitory effects of the single drug schedules.
Combination of Axitinib and SN-38 Inhibits ABCG2 and
ATP7A Gene Expression in Endothelial and Cancer Cells
To study the effect of the combination treatment to the variation
of ATP7A and ABCG2 expression, the gene expression of these trans-
porters was quantified in all the three cell lines exposed to different
drug concentrations. Figure 4, A and B, showed the concentration-
dependent and significant inhibition of the gene expression of ATP7A
and ABCG2 in Capan-1 and MIAPaCa-2 cells, respectively, by
Table 1. CI and DRI Values for the Drug Combinations at 25%, 50%, and 75% Levels of Inhibition
of HMVEC-d, Capan-1, and MIAPaCa-2 Cell Proliferation.
Cells CI Values
25%
(Axitinib +SN-38)
50%
(Axitinib + SN-38)
75%
(Axitinib + SN-38)
HMVEC-d 0.008 0.082 0.877
Capan-1 1.074 0.711 0.473
MIAPaCa-2 0.219 0.173 0.173
Cells DRI Values
25% 50% 75%
Axitinib SN-38 Axitinib SN-38 Axitinib SN-38
HMVEC-d >500 144.228 75.497 14.447 5.368 1.447
Capan-1 2.891 1.373 4.898 1.974 8.298 2.837
MIAPaCa-2 4.930 62.436 7.283 27.887 10.760 12.456
Figure 1. Effect of axitinib and SN-38, the active metabolite of irinotecan, on in vitro cell proliferation (A-C). The antiproliferative effects
of the drugs were studied using continuous exposures (72 hours) on HMVEC-d (A), Capan-1 (B), and MIAPaCa-2 cell lines (C). Symbols
and bars indicate mean values ± SE, respectively. *P < .05 versus vehicle-treated controls. IC50 indicates the concentration of drug that
reduced cell proliferation by 50%. Isobologram analyses of HMVEC-d (D), Capan-1 (E), and MIAPaCa-2 (F) cell proliferation inhibition by
simultaneous combination of axitinib and SN-38. The IC50 and IC90 values of each drug are plotted on the axes; the solid line represents the
addictive effect, whereas the point representing the concentrations of axitinib and SN-38 resulting in 50% or 90% proliferation inhibition
of the combination is reported on the left of the connecting line, indicating synergism.
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axitinib, SN-38, and their simultaneous combination. Moreover, in
HMVEC-d cells, the combination of the two drugs caused significant
decreases in the expression of ATP7A and ABCG2 at much lower con-
centrations of the two drugs (Figure 4C).
On the basis of these findings, we measured the intracellular con-
centration of SN-38 in treated cells. Higher SN-38 concentrations
were found in endothelial cells exposed to the combined schedule
if compared with treatment using single drug alone, as demonstrated
by the area under the peak of the chromatograms (Figure 5, A-E ).
Figure 5F quantified the significant increase of intracellular SN-38
concentration normalized to 105 cells.
SN-38 and Axitinib Combination Increased the Secretion of
TSP-1 in Conditioned Media and Decreased VEGFR-2 in
HMVEC-d Cells
The exposure of endothelial cells to axitinib and SN-38 for 72 hours
at concentrations that determined a 50% inhibition of cell proliferation
determined a significant increase of TSP-1 secretion in the medium
and a decrease in VEGF secretion (Figure 6A). Of note, the same per-
centage of TSP-1 increase was obtained by the simultaneous exposure
to axitinib and SN-38 at much lower concentrations.
Moreover, the drug combination significantly decreased the
VEGFR-2 protein level in endothelial cell lysates in a concentration-
dependent manner (Figure 6B), even at very low concentrations.
Axitinib Improves the Antitumor Activity of Irinotecan In Vivo
Capan-1 cells injected subcutaneously (s.c.) in CD nu/nu mice
grew quite rapidly, and tumor masses became detectable 8 to 10 days
after xenotransplantation. Tumors in control animals showed a expo-
nential enlargement in their dimensions. Both axitinib and CPT-11,
alone and in combination, were able to inhibit tumor growth, although
to different extents (Figures 7 and W1A). During the 31 days of treat-
ment, axitinib was significantly effective at inhibiting tumor growth
(e.g., at day 31, 136.8 vs 1389 mm3 of controls, P < .05) and greater
than CPT-11 (476.2 mm3). In the group of animals receiving the com-
bined treatment of axitinib and CPT-11, regression of tumors was
almost complete (e.g., at day 31, 67.9 mm3), and it was always sig-
nificant when compared to CPT-11 and on days 14 and 17 also when
compared to axitinib (Figures 7 and W1B). The toxicity profile was
favorable for axitinib, with no loss of weight throughout the course
of the experiment (Figure W2). As expected, the mice treated with
CPT-11 showed a 15% of weight loss compared with controls, whereas
the combination treatment caused a maximum weight loss of 30%
(Figure W2). Mouse weights successfully recovered with simple veteri-
nary assistance consisting in a fluid therapy (0.9% saline, 40-80 ml/kg
s.c. every 24 hours) as recommended by the academic committee for
the animal experimentation and by the guidelines of animals in cancer
research [32]. No toxic deaths occurred.
The subcutaneous injection of Capan-1 pancreatic cancer cells caused
tumors, the histologic picture of which was consistent with pancreatic
cancer. As shown in Figure 8A, treatment using the simultaneous com-
bination of axitinib and CPT-11 significantly reduced the microvessel
count in the tumor mass when compared to controls. Panels B and
C of Figure 8 are representative microscopic pictures of the quantified
reduction of microvessels in the control and treated tumors with the
combination schedule.
As shown in Figure 8D, tumors administered with the combina-
tion treatment determined a significant increase in tumor apoptosis
Figure 2. Proapoptotic effects of SN-38 and axitinib on proliferating HMVEC-d (A, upper part), Capan-1 (B, upper part), and MIAPaCa-2
(C, upper part) cells treated for 72 hours. The enhanced proapoptotic effects of the combined treatment was determined on HMVEC-d
(A, lower part), Capan-1 (B, lower part) and MIAPaCa-2 (C, lower part) cells. Columns and bars indicate mean values ± SE, respectively.
*P < .05 versus vehicle-treated controls. Control− stands for the negative control of the ELISA kit.
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as demonstrated by increased activated caspase-3 staining of paraffin-
embedded specimens, if compared to controls and single drugs alone.
Panels E and F of Figure 8 are representative microscopic pictures of
the quantified increase of caspase-3 staining in the control and treated
tumors with the combination schedule.
Discussion
There is an increasing interest in the clinical development of axitinib, an
oral inhibitor of VEGF receptors-1, -2, and -3 having proven anti-
angiogenic effect [4]. Indeed, the drug has demonstrated a wide range
of activity against various tumors in phase 2 studies, including thyroid
cancer [33], advanced non–small cell lung cancer, and metastatic renal
cell carcinoma [34,35], as well as pancreatic cancer in combination with
gemcitabine [1]. Recently, original combinations of chemotherapeu-
tic schedules were reported in the context of a phase 1 study on meta-
static colorectal cancer and other solid tumors, including axitinib in
combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin),
or FOLFOX (oxaliplatin, 5-fluorouracil, leucovorin) and with or with-
out bevacizumab [36]. In fact, axitinib, given at a starting dosage of
5 mg twice a day, was well tolerated in combination with FOLFOX
or FOLFIRI, with no dose-limiting toxicities observed [36]. Moreover,
this combination is currently being tested in an ongoing, open-label,
randomized, multicenter phase 2 clinical trial (NCT00615056), illus-
trating the clinical interest in assessing axitinib with schedules contain-
ing irinotecan.
Our study clearly demonstrated, for the first time, that the axitinib
and irinotecan combination was highly synergistic in vitro, targeting
both endothelial and pancreas cancer cells. This is of considerable in-
terest not only for the ongoing colorectal cancer trials but also for plan-
ning new pancreas cancer treatments in the future. In this regard, this
tumor type has clinically been shown to have a significant inherent
resistance to chemotherapeutic drugs and anti-VEGF treatments
[37]; thus, a novel synergistic approach is urgently needed based on
novel mechanism of actions. The previous preclinical data are almost
all related to the in vivo inhibition of tumor growth and angiogenesis
by axitinib [4,6,10], and no data are available on the extent of anti-
proliferative and proapoptotic effect in vitro both alone or in combi-
nation with chemotherapeutic drugs on proliferating endothelial and
Figure 3. Modulation of Akt (pThr308) and ERK1/2 (pThr185/pTyr187) phosphorylation by axitinib, SN-38, and their combination in HMVEC-d
(A), Capan-1 (B), and MIAPaCa-2 (C) cells after 72 hours of treatment. pAkt and pERK1/2 concentrations were measured by ELISA kits, and
they were normalized to total Akt and ERK1/2 protein concentration, respectively. Columns and bars indicate mean values ± SE, respec-
tively. *P < .05 versus vehicle-treated controls.
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cancer cells. Interestingly, here we show that the antiproliferative and
proapoptotic effects are also significant when tested on cancer cells
(albeit at higher concentrations compared to endothelial) by axitinib
alone, probably related to the inhibition of different tyrosine kinases
(e.g., FGFR-1, platelet-derived growth factor receptor) and protein
kinases such as Abl and Aurora-2 as demonstrated by Hu-Lowe et al.
[4] and by the synergistic action of the simultaneous combination with
SN-38. Axitinib has been shown to inhibit in vitro both ERK1/2 and
Akt phosphorylation in human umbilical vascular endothelial cells and
ERK1/2 phosphorylation in tumor samples [4]. Our findings confirm
these data in endothelial cells and suggest that cancer cells could be di-
rectly affected in the proliferation/apoptosis rate by axitinib through
the ERK1/2 and Akt phosphorylation inhibition. Moreover, these ef-
fects are amplified by the simultaneous combination of SN-38 and
axitinib at much lower concentrations than the single drugs alone, both
in endothelial and cancer cells, indicating that it is possible to obtain
the same intracellular signal transduction inhibition by markedly re-
ducing the doses of both drugs, as also clearly suggested by the experi-
mental DRIs.
The basis of the significant synergistic activity of the SN-38/irinotecan
plus axitinib combination may be the increase of intracellular SN-38
concentration observed after the simultaneous exposure to the two
drugs. The inhibition of the gene expression of two relevant transpor-
ters of SN-38 such as ATP7A and ABCG2, both involved in the re-
sistance to irinotecan and other chemotherapeutic drugs [23,26,38],
by the simultaneous combination of the drugs, sheds light on the
possible mechanism by which the intracellular levels of the active
metabolite of irinotecan are significantly increased. Indeed, there is
an increasing evidence regarding the capacity to directly inhibit ABC
transporters P-glycoprotein by similar drugs such as sunitinib [39,40]
or to reduce ABCG2 surface expression in cancer cells by other tyrosine
kinase inhibitors like imatinib, nilotinib, and dasatinib [41]. Thus, it is
conceivable that the simultaneous administration of axitinib and SN-38
can inhibit expression of ATP7A and ABCG2 at both the mRNA or
the protein levels and their functional activity.
Another interesting finding of our study concerns the significant
decrease, in a concentration-dependent manner, of VEGFR-2 protein
in endothelial cell lysates after the administration of the combination
Figure 4. ATP7A and ABCG2 gene expression in Capan-1 (A), MIAPaCa-2 (B), and HMVEC-d (C) cells exposed to axitinib, SN-38, the
simultaneous combination of axitinib and SN-38, or with vehicle alone for 72 hours. Columns and bars indicate mean values ± SE,
respectively. *P < .05 versus vehicle-treated controls.
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treatment. This finding could explain the necessity of lower doses of
the VEGFR-2 inhibitor drug to maintain a similar inhibition of intra-
cellular signal transduction and the same effects on blocking cell pro-
liferation and promoting the apoptosis process. Moreover, a report by
Lee et al. [42] showed that intracellular autonomous VEGF/VEGFR-2
signaling had an indispensable role in vascular homeostasis and endo-
thelial cell survival and that intracellular VEGFR-2 activation in endo-
thelial cells was suppressed by a small-molecule VEGFR antagonist.
Thus, it is possible that the drug combination may potently decrease
both transmembrane and intracellular VEGFR-2 protein, maintaining
even at lower doses the inhibition of VEGFR-2 phosphorylation and
autophosphorylation mediated by exogenous VEGF in endothelial cells
[42] that ultimately induce endothelial cell apoptosis. Furthermore, nu-
merous studies have reported a significant decrease of plasma soluble
VEGFR-2 during and after treatment with VEGFR-2 tyrosine kinase
inhibitors such as sunitinib and sorafenib, both in treated animals [43]
and in patients [44–47], suggesting a possible use of this receptor as a
biomarker of these inhibitors. Recently, Mukohara et al. [48] described
in a phase 1 clinical study the significant decrease of sVEGFR-2 by
axitinib in Japanese patients, with a significant correlation between
these changes and the area under the curve of the drug (P < .0001).
In this regard, our in vitro findings could represent a possible explana-
tion of these previously reported clinical data.
It is noteworthy that the increase of TSP-1, an endogenous inhib-
itor of angiogenesis, and a decrease of VEGF secretion in the condi-
tioned media of endothelial cells at effective concentrations of the
two combined drugs may be additional mechanisms to explain the
efficacy of the drug combination. Our group has previously observed
that SN-38 caused a significant increase of TSP-1 in conditioned
medium of microvascular endothelial cells after 72 hours of treatment
[28]. This enhancement of TSP-1 was maintained and even increased
in the combined treatment but at lower doses. This observations may
be mechanistically linked to the inhibition of Akt phosphorylation as
demonstrated by Bussolati et al. [49], who described the modulatory
Figure 5. Intracellular SN-38 concentration measurement in HMVEC-d cells after the exposure to axitinib, SN-38, and their simultaneous
combination for 72 hours. Representative high-performance liquid chromatography chromatograms of a spiked standard of SN-38 (A), drug-
free vehicle-treated sample (blank, B), axitinib-treated sample (C), SN-38-treated sample (D), and axitinib + SN-38 combination sample (E).
Interfering peaks were not noted at the retention time of SN-38 (arrow) in the drug-free sample. Quantification of the SN-38 concentrations
in 105 HMVEC-d cells (F). Columns and bars indicate mean values ± SE, respectively. *P < .05 versus SN-38–treated samples.
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role of Akt on TSP-1 synthesis in tumor endothelial cells. Indeed,
the inhibition of Akt activation by administration of PI3K inhibitors
significantly stimulated the synthesis and release of TSP-1 in tumor
endothelial cell [49], in agreement with previous data by Niu et al.
[50], who have shown that a loss of Akt signaling was related to a gradual
increase in TSP-1 levels in endothelial cells.
To proceed with the development of the concurrent combination
of CPT-11 and axitinib, the second step was to evaluate the anti-
tumor and antiangiogenic activity of this schedule in vivo. On the
basis of our previous experience [28] and from data of previously
published studies [4], we decided to treat animals with an maximum
tolerated dose (MTD) CPT-11 regimen (100 mg/kg weekly), an
optimal dose axitinib schedule (25 mg/kg p.o. twice/day), and with
the simultaneous combination of this two regimens. The axitinib
schedule was very well tolerated, as expected from the published
experience in other tumor models [4], when compared with the
CPT-11 MTD regimen. Moreover, the results suggested an improved
efficacy of the combined regimen (at least for some time points), with
a significant but still acceptable toxicity profile if a simple veterinary
assistance (saline injections) was provided; this enhanced activity
was due to the combination of a direct effect of irinotecan MTD
dose on both drug-sensitive tumor cells and proliferating endothelial
cells [51,52] and to a prolonged antitumor and antiangiogenic effect
in vivo of axitinib [4]. Indeed, the continuous administration of the
Figure 6. TSP-1 and VEGF secretion (A) in the conditioned media of HMVEC-d cells exposed to axitinib, SN-38, and their simultaneous
combination or with vehicle alone for 72 hours. Columns and bars indicate mean values ± SE, respectively. *P < .05 versus vehicle-
treated controls. TSP-1 and VEGF concentrations in conditioned media were measured with ELISA kit and normalized to total protein
concentration. VEGFR-2 concentration (B) in 6 × 105 HMVEC-d cell lysate after the exposure to axitinib, SN-38, and their simultaneous
combination or with vehicle alone for 72 hours. Columns and bars indicate mean values ± SE, respectively. *P < .05, **P < .001 versus
vehicle-treated controls.
Figure 7. In vivo antitumor effects of the single drugs (irinotecan 100 mg/kg i.p. every week and axitinib 25 mg/kg p.o. twice/daily) and
simultaneous combination of irinotecan and axitinib schedules on Capan-1 tumors xenotransplanted in CD nu/numice expressed as percent
T /C value. Columns indicate percent T/C values. *P< .05 axitinib alone and axitinib + irinotecan versus irinotecan alone; #P< .05 axitinib +
irinotecan versus axitinib alone. A indicates axitinib; A + I, axitinib + irinotecan; I, irinotecan.
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VEGFR-2 tyrosine kinase inhibitor alone or in combination with
CPT-11 without any breaks was extremely important because it caused
an almost complete tumor regression, avoiding the observed rapid
tumor (re)growth seen after cessation of therapy with tyrosine kinase
inhibitors [43,53].
No preclinical data are currently available on the irinotecan and
axitinib combination; however, a phase 1 study of axitinib and irinotecan,
but combined with 5-fluorouracil and leucovorin, in patients with
advanced colorectal cancer has been recently published, describing
an acceptable toxicity profile [36]. Our data experimentally support the
preclinical advantage of the association between the continuously ad-
ministered axitinib and MTD CPT-11 in pancreas cancer and may
rapidly improve the possibility to translate this combination therapy
into the clinic on a solid basis to enhance the antitumor effects and re-
duce toxicity. Indeed, our data clearly suggest the possibility to reduce
the doses of both drugs, maintaining the same antiangiogenic and anti-
tumor effects.
In conclusion, the clinical development of a promising irinotecan/
axitinib schedule and of related pharmacodynamicmechanisms, appears
possible. The significance of our results is the development of a rational
and less empirical strategy for irinotecan/axitinib combination “from
bench to bedside”. Indeed, our study focuses on possible new ap-
proaches with respect to addressing the major questions regarding the
clinical application of combined schedules between chemotherapeutic
drugs and VEGFRs inhibitors that relate to the actual antitumor/
antiangiogenic activity of the chosen combination, the dosing levels,
the frequency of administration, the possible pharmacodynamic sur-
rogate markers to be used to monitor the therapy (e.g., ATP7A and
ABCG2 gene expression, VEGFR-2 and TSP-1 protein concentra-
tion). Indeed, based on our experimental data, we could suggest initiat-
ing pilot phase 2 clinical trials with at least the following characteristics:
1) a simultaneous combination of irinotecan and daily axitinib without
any breaks in pancreas cancer patients (including patients whose tumors
are already resistant to irinotecan, but who may respond again because
of the inhibition of ATP7A and ABCG2 transporters), 2) the irinotecan
and axitinib dose levels being reduced with respect to their maximum
tolerated total dose or optimal biologic dose, and 3) the antitumor/
antiangiogenic activity assessed with pharmacodynamic parameters
Figure 8. Quantification of microvessel density in Capan-1 tumor xenografts administered with vehicle, irinotecan 100 mg/kg i.p. every
week, axitinib 25 mg/kg p.o. twice/daily, and their simultaneous combination schedule at the end of 31 days of treatments (A). Columns
and bars indicate mean values ± SE, respectively. *P < .05 versus vehicle-treated controls. Representative images of IHC of mouse FVIII
in Capan-1 xenografts in vehicle-treated mice (control group) (B) and in irinotecan 100 mg/kg i.p. every week + axitinib 25 mg/kg p.o. twice/
daily group of mice (C). Quantification of tumor apoptosis as detected by caspase-3 staining (D). Columns and bars indicate mean values ±
SE, respectively. *P < .05 versus vehicle-treated controls; #P < .05 versus axitinib- and irinotecan-treated alone groups. Representative
images of IHC of active caspase-3 in Capan-1 xenografts in vehicle-treated mice (control group) (E) and in irinotecan 100 mg/kg i.p. every
week + axitinib 25 mg/kg p.o. twice/daily group of mice (F). Arrowheads indicate positively stained cells. Magnification, ×200.
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such as, for example, ATP7A and ABCG2 gene expression in peripheral
blood mononuclear cell, or VEGFR-2 and TSP-1 plasma levels.
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Figure W1. (A) Antitumor effect of 1) irinotecan 100 mg/kg i.p., 2) axitinib 50 mg/kg p.o., and 3) simultaneous combination of irinotecan and
axitinib on Capan-1 tumors xenotransplanted in CD nu/numice. (B) Magnification of both axes for the tumor volume of treated groups only.
Symbols and bars indicate mean ± SEM.
Figure W2. Bodyweight of Capan-1 tumor-bearing control mice and
mice treated with irinotecan, axitinib, and their simultaneous combi-
nation. Irinotecan and the irinotecan/axitinib combination caused a
loss of weight that required veterinary assistancewith a fluid therapy
(0.9% saline, 40-80 ml/kg s.c. every 24 hours). Symbols and bars
indicate mean ± SEM. P < .05 versus vehicle-treated controls.
